This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward- looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology.
Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the current war between Israel, Hamas and Hezbollah and any worsening of the situation in Israel such as further mobilizations or escalation in the northern border of Israel and those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".
Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.
The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.
2 | 2 | |
About Evogene
4
DECODING BIOLOGY
OUR
PIONEER GROUNDBREAKING LIFE- SCIENCE PRODUCTS ROOTED IN MICROBES, SMALL MOLECULES, AND GENOMICS
5
MICROBES | SMALL MOLECULES |
GENETIC ELEMENTS
Microbials for crops
Food
Human & animal probiotics
Plastic
degradation
Therapeutic microbials
Dietary supplements
Probiotics
Waste-water
treatments
Crop protection
Chemical stimulants
Animal fertility
Animal healthcare
Pharmaceuticals
Advanced wound care
Medical device coating
Alternative food
Improved crops
Bio fuel
Medical
Cannabis
Gene therapy
Cell therapy
Diagnostics & precision medicine
Novel
Chemicals
Source for
enzymes
Oil spill clearing
Flavors and Fragrances
enzymes
Fragrances | Natural food |
coloring |
OF LIFE SCIENCE PRODUCT DEVELOPMENT
Low probability of success with high cost and long time-tomarket
Pharma
Industry
Cost of developing a single
pharmaceutical drug*
In the 1970's
$180M
In recent years
> $2,000M
Ag-chemicals
Industry
Years to develop a new crop
protection product**
1995
8Y
2000
9Y
2005-2008
10Y
2010-2014
11+Y
*Phillips McDougall, 2016. **https://www.forbes.com/sites/matthewherper/2017/10/16/the-cost-of-developing-drugs-is-insane-a-paper-that-argued-otherwise-was-insanely-bad/?sh=7533aa82d459
7
LIFE-SCIENCE PRODUCTS LONG-TAIL PROCESS
THE CHALLENGE
finding the winning candidates out of a vast number of possible prospects that address a complex myriad of criteria, to reach higher success rate for products
> DISCOVERY | > OPTIMIZATION | > DEVELOPMENT | > REGULATION |
"Needle | ||
in the | Approved | |
haystack" | ||
Product | ||
T I M E / M O N E Y
8
TODAY WE
ARE ON THE
BRINK OF A
Computational technology advancements enable the discovery and optimization of the most promising candidates, addressing multiple development challenges towards successful life-science based products
LIFE-
SCIENCE
LIFE-SCIENCE PRODUCT DEVELOPMENT
Acceleration Optimization Efficiency
9
DECODING BIOLOGY
WE MERGE LIFE-SCIENCE WITH BIG DATA AND CUTTING- EDGE AI TECHNOLOGIES TO EFFECTIVELY DISCOVER
AND OPTIMIZE BREAKTHROUGH LIFE-SCIENCE BASED PRODUCTS
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Evogene Ltd. published this content on 29 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 May 2024 11:07:03 UTC.